Proton pump inhibitor (PPI) effectiveness in GERD is significantly influenced by CYP2C19 genetic polymorphisms affecting drug metabolism.
Surgically treated patients with GERD exhibit a higher prevalence of CYP2C19 rapid and ultrarapid metabolizer phenotypes compared to medically managed patients.
CYP2C19 testing could guide PPI dose adjustments and early surgical referral to optimize GERD management outcomes.
This study is among the first to demonstrate the clinical utility of pharmacogenomic profiling in adult GERD treatment strategies.
